Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Menoufia University
Metastatic non-small cell lung cancer patients after receiving their first line systemic therapy according to their genetic mutation will be randomized to follow up versus radiotherapy to the primary lesion.
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Confirmed histological diagnosis of NSCLC.
2. Stage IV disease.
3. Patients with P.S ≤ 2.
4. finished at least 4 cycles of platinum-based doublet chemotherapy if patient has no diver mutation, or at least 3 months of anti-EGFR, Anti-ALK according to their driver mutation with SD, PR or CR.
You may not be if
1. History of prior irradiation to the lung.
2. residual Malignant pleural or pericardial effusion at randomization time.
3. History of prior malignant tumor likely to interfere with the treatment protocol.
4. Severe comorbidities as measured by morbidity index.
5. Disease progression on first line systemic therapy.
Clareo Health | Radiotherapy to the Primary in Metastatic Non-small Cell Lung Cancer Patients
